LUNG

AI Memo

Pulmonx

As of 2026-04-29/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-04-29 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q1 2026 earnings release is the immediate unresolved swing factor • 2026-04-29

Expected move: -28%

Biggest risk

The bear read is that the March 2026 reset already implied a low bar, yet 2026 guidance was roughly flat to 2025 revenue and still called for meaningful cash use; any Q1 miss, weaker U.S. procedure trend, or softer liquidity outlook would likely push investors back to financing risk first.

Invalidation

Break below $1 or thesis failure.

What would change my mind?

The best post-print bull read would be confirmation that first-quarter demand did not deteriorate versus the March setup, especially if management can keep 2026 revenue guidance intact while showing operating-expense discipline and no sharper-than-planned cash burn.

Research note

Recommendation

—

Confidence

medium

As of

2026-04-29

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Flat 2026 outlook and financing terms keep balance-sheet pressure front and center
Zephyr adoption and U.S.
reacceleration remain the only clean path to a rerating

BearKey bullets

2026 revenue guidance of $90 million-$92 million is only around flat with 2025 revenue of $90.5 million, which is a modest setup for a company that still needs adoption-driven growth to escape balance-sheet scrutiny.
As of April 29, 2026, the checked company IR and SEC-filings pages did not yet show the Q1 2026 earnings release or a new earnings 8-K, so the key surprise/guidance datapoint for this follow-up run is still missing.
Fourth-quarter 2025 U.S.

WatchKey bullets

Q1 2026 earnings release is the immediate unresolved swing factor

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $1 (p=45%)

Bull/Bear spread: +73% / -64%

Vs latest close: Bull +73% · Base -28% · Bear -64%

Scenario probabilities

Bull Target: $2 (p=25%)Base Target: $1 (p=45%)Bear Target: $1 (p=30%)

Commentary

This remains a cautious monitoring memo, not a confirmed post-earnings thesis change. As of April 29, 2026 UTC, Pulmonx's investor-relations news page still showed the April 15 scheduling release rather than posted Q1 2026 results, and the company SEC-filings page showed no newer earnings filing than the March 2026 items checked here. That means earnings surprise, analyst revisions, and immediate post-print price reaction were unavailable for confirmation in this T+1 run, so the deterministic negative prior still carries more weight than narrative hope.

As of 2026-04-29 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Flat 2026 outlook and financing terms keep balance-sheet pressure front and center
Zephyr adoption and U.S. reacceleration remain the only clean path to a rerating

Scenarios

Bull Target (Scenario probability)

$2 / p=25% prob

Base Target (Scenario probability)

$1 / p=45% prob

Bear Target (Scenario probability)

$1 / p=30% prob

Price $1 as of 2026-06-24

Nearest Scenario: Base (∆ 28%)

Targets vs latest close: Bull +73% · Base -28% · Bear -64%

Sentiment & Exposure

News Sentiment (30d)

-0.24

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-04-29
Q1 2026 earnings release is the immediate unresolved swing factor
Pulmonx said on April 15, 2026 that it would report first-quarter 2026 financial results after the close on April 29, 2026, but as of the company pages checked for this run the result itself was not yet posted, leaving revenue, cash-burn trajectory, guidance confirmation, and the first market read-through unconfirmed [#IR-2026-04-15].
Prob 85.00% • Move 22.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

Flat 2026 outlook and financing terms keep balance-sheet pressure front and center
2026-12-31
Pulmonx guided 2026 revenue to $90 million-$92 million versus $90.5 million in 2025, expects about $23 million of cash usage in 2026 absent extra drawdowns, and refinanced with a Perceptive facility whose undrawn tranches depend on revenue milestones; that leaves little room for a commercial miss before financing risk becomes the dominant equity narrative [#PR-2026-03-04] [#8-K-2026-03-05] [#10-K-2026-03-10].
Prob 70% • Move -18% • Priced-in 67%

Long-term Catalysts

Months to a year

Zephyr adoption and U.S. reacceleration remain the only clean path to a rerating
2026-12-31
Management framed 2025 as a transition year and said the operating plan is aimed at reaccelerating commercial growth while advancing the clinical pipeline; the underlying setup is still a concentrated Zephyr story, with fourth-quarter 2025 U.S. revenue down 11% year over year even as international revenue grew 8%, so a durable rerating still requires proof that procedure demand and hospital adoption can improve in the core business [#PR-2026-03-04] [#10-K-2026-03-10].
Prob 35% • Move 28% • Priced-in 55%

Risks

2026 revenue guidance of $90 million-$92 million is only around flat with 2025 revenue of $90.5 million, which is a modest setup for a company that still needs adoption-driven growth to escape balance-sheet scrutiny.
As of April 29, 2026, the checked company IR and SEC-filings pages did not yet show the Q1 2026 earnings release or a new earnings 8-K, so the key surprise/guidance datapoint for this follow-up run is still missing.
Fourth-quarter 2025 U.S. revenue fell 11% year over year, so the core question is still whether domestic Zephyr procedure demand can stabilize rather than whether the company can simply cut costs.
Pulmonx ended 2025 with $69.8 million of cash, cash equivalents, and marketable securities and guided to roughly $23 million of 2026 cash usage absent additional drawdowns, limiting room for execution misses.
The Perceptive credit facility improves maturity but introduces milestone dependence and default-rate step-up risk, keeping financing terms relevant to equity downside.

Peers

Symbol	Summary
BEAT	HeartBeam is the closest size-risk comparator in the packet, even though the product set is different; it is more useful as a small-cap medtech financing and execution read-through than as a direct procedural-demand comp.
BSX	Boston Scientific is a broad hospital-selling device benchmark rather than a close peer, but it highlights how far Pulmonx remains from the scale, diversification, and commercial consistency of a mature platform.
EW	Edwards Lifesciences is another evidence-driven device benchmark with better procedural depth and margin structure; the comparison mostly reinforces that Pulmonx is still a fragile niche medtech story.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-04-29

AI Stock Memo: LUNG - Pulmonx - RankAlpha